Vanda Pharmaceuticals to Announce Third Quarter 2012 Financial Results on November 7, 2012

Conference Call and Webcast to Follow

WASHINGTON, Oct. 17, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the third quarter of 2012 on Wednesday, November 7, 2012, before the market opens.

The Company will host a conference call at 10:00 AM ET on Wednesday, November 7, 2012, during which Vanda management will discuss the financial results.  To participate in the conference call, please dial 1-800-299-7089 (domestic) or 1-617-801-9714 (international) and use passcode 66514556.

The conference call will be broadcast simultaneously and archived on the Company's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Wednesday, November 7, 2012, beginning at 12:00 PM ET and will be accessible until Wednesday, November 14, 2012, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The passcode number is 34968750.

ABOUT VANDA PHARMACEUTICALS INC.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Company Contact:          
Cristina Murphy
Senior Communications Manager                      
Vanda Pharmaceuticals Inc.                              
(202) 734-3400                                                              
[email protected]  

SOURCE Vanda Pharmaceuticals Inc.

Suggested Articles

The culture change is part of an effort to stop the fear of failure from pushing GSK researchers to make conservative decisions. 

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.